Semaglutide could help people drink less alcohol. Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help people drink less alcohol. A ...

Semaglutide could be a potential treatment option for patients with alcohol use disorders. It can reduce alcohol consumption, prevent relapse-like drinking during alcohol withdrawal, and attenuate ...

GLP-1 drugs may protect the liver but raise blood alcohol levels. Yale researchers are investigating how this dual effect impacts health. Anti-obesity drugs such as semaglutide (Ozempic, Wegovy), are ...

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new research led by Christian ...

Share on Pinterest Semaglutide drugs were tied to a significantly lower incidence of alcohol use disorder in a new study. Image credit: JNemchinova/Getty Images. A new study from Case Western Reserve ...

Scientists are testing whether GLP-1 drugs can help to cut cravings for cigarettes, alcohol and opioids — as well as food.

A Yale study finds GLP-1 drugs like Ozempic and Wegovy may slow alcohol breakdown, raising blood alcohol levels even as they reduce liver-toxic byproducts.

People with alcohol use disorder who took semaglutide, also known as Wegovy, drank less and had fewer cravings for alcohol, new research found. Reading time 3 minutes A study out this week suggests ...

Phase 2 trial shows significant reduction in drinks per drinking day and weekly alcohol craving. (HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in ...

2/20/25 (LAPost.com) — New research suggests semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, could help people reduce their alcohol consumption. The study, published in JAMA ...

A long-term study suggests GLP-1 agonists, especially semaglutide, may lower the risk of alcohol use disorder hospitalizations, highlighting the potential for novel treatments pending further clinical ...